Given that SOX10 can also negatively regulate EGFR expression139—whose overexpression is a recognized driver of BRAFi resistance148—the combined repression of EGFR through concurrent overexpression of both SOX10 and miR‐7 presents a potentially synergistic approach for sensitizing resistant melanoma cells to BRAFi therapy, deserving further investigation in preclinical and clinical settings. Here, SOX10 is linked to melanoma.